NasdaqGM:OCSPharmaceuticals
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate
Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received Priority Medicines (PRIME) designation from the European Medicines Agency for treating optic neuritis, following an earlier Breakthrough Therapy designation from the U.S. FDA.
This dual fast-track regulatory support, backed by Phase 2 ACUITY trial data and Orphan Drug status, spotlights Privosegtor’s potential role in a rare disease market estimated at US$7.00 billion in the U.S. alone.
We’ll now...